(CercleFinance.com) – On the occasion of the resumption of quotations of ordinary shares of Valneva on Euronext Paris at 4:30 p.m., the title arrogates more than 18%.
The course had been suspended at the request of the Company from 9 a.m. pending a press release from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
The CHMP has announced that it is recommending marketing authorization (MA) in Europe for its candidate vaccine against Covid-19 for primary vaccination in adults aged 18 to 55.
The European Commission must now decide. His decision is expected ‘soon’.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
